2026年2月3日，WuXi XDC Cayman Inc.（药明合联生物技术有限公司，股票代码：02268）披露截至2026年1月31日的股份变动月报表。报告期内，法定股本保持在10,000,000,000股，面值每股0.00005美元，总额500,000美元未发生变动。
报告期初已发行股份总数为1,255,240,986股，期末增至1,257,992,705股，新增2,751,719股。公司确认符合香港联交所对公众持股量的相关要求。
根据公告，新增股份主要来自期权行使，涉及数量共计2,751,719股。本月因期权行使所获资金累计约人民币5,213,127.55元。报告期内无股份回购、注销或库藏股变动。另有2024年股份计划所授出的潜在股份10,285,226股尚未正式发行。
截至1月底，公司股本总数增加至1,257,992,705股。公司声明遵守香港联交所《上市规则》及相关法律法规。公告由执行董事、首席财务官兼公司秘书席晓捷签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.